生长激素释放激素可降低HIV合并NAFLD患者的循环免疫激活标志物并与肝脏免疫通路效应平行
该双盲随机试验在61例HIV感染合并非酒精性脂肪性肝病(NAFLD)患者中比较替莫瑞林与安慰剂12个月的效果。替莫瑞林显著降低13种循环蛋白(包括趋化因子、细胞因子和T细胞相关分子),无蛋白升高,肝脏转录组证实免疫激活通路下调。提示增强生长激素轴可能改善HIV代谢紊乱患者的免疫激活。
要点
- 替莫瑞林治疗12个月降低HIV合并NAFLD患者循环中13种免疫激活相关蛋白。
- 降低的蛋白涉及细胞毒性T细胞和单核细胞活化,肝组织转录组证实免疫通路下调。
- 增强生长激素轴可能成为减轻HIV患者系统性及终末器官免疫激活的策略。
核心结论
- 长期使用GHRH类似物替莫瑞林可降低HIV合并NAFLD患者的T细胞和单核/巨噬细胞活化标志物。
研究设计与样本
- 双盲随机对照试验,纳入61例HIV合并NAFLD患者,替莫瑞林与安慰剂对比12个月,检测血浆92种免疫/趋化/代谢生物标志物并行肝活检基因集富集分析。
主要发现
- 替莫瑞林组较安慰剂组显著降低13种循环蛋白,无蛋白升高。
- 降低的蛋白包括4种趋化因子(CCL3、CCL4、CCL13、IL8)、2种细胞因子(IL-10、CSF-1)、4种T细胞相关分子(CD8A、CRTAM、GZMA、ADGRG1)以及ARG1、Gal-9和HGF。
- 网络分析显示这些蛋白相关基因通路密切相互作用,插补分析提示一组免疫通路下调。
- 肝组织靶向转录组证实免疫激活通路显著下调的终末器官信号。
临床怎么用
- 对于HIV合并NAFLD且代谢紊乱、存在系统性炎症的患者,GHRH类似物可能有助于减轻免疫激活,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis modulates critical metabolic pathways; however, little is known regarding effects of augmenting pulsatile GH secretion on immune function in humans. This study used proteomics and gene set enrichment analysis to assess effects of a GH releasing hormone (GHRH) analog, tesamorelin, on circulating immune markers and liver tissue in people with human immunodeficiency virus (HIV) (PWH) and nonalcoholic fatty liver disease (NAFLD). METHODS: 92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months. Gene set enrichment analysis was performed on serial liver biopsies targeted to immune pathways. RESULTS: Tesamorelin, compared to placebo, decreased interconnected proteins related to cytotoxic T-cell and monocyte activation. Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin. These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF. Network analysis indicated close interaction among the gene pathways responsible for these proteins, with imputational analyses suggesting down-regulation of a closely related cluster of immune pathways. Targeted transcriptomics using liver tissue confirmed a significant end-organ signal of down-regulated immune activation pathways. CONCLUSIONS: Long-term treatment with a GHRH analog reduced markers of T-cell and monocyte/macrophage activity, suggesting that augmentation of the GH axis may ameliorate immune activation in an HIV population with metabolic dysregulation, systemic and end organ inflammation. Clinical Trials Registration. NCT02196831.
引用
- Stanley TL, Fourman LT, Wong LP, et al. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021. PMID: 33852720. doi:10.1093/cid/ciab019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。